rs148564534

Variant summary

Our verdict is Benign. The variant received -10 ACMG points: 0P and 10B. BP4BS3_SupportingBA1

This summary comes from the ClinGen Evidence Repository: The NM_001482.3:c.407C>T variant in GATM is a missense variant predicted to cause substitution of threonine by methionine at amino acid 136 (p.Thr136Met). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0007357 (95/129130 alleles) in the non-Finnish European population, which is higher than the ClinGen CCDS VCEP’s threshold for BA1 (>0.0005), and therefore meets this criterion (BA1). Expression of the variant in HeLa cells resulted in >50% wild type AGAT activity suggesting that this variant does not significantly impact protein function (PMID:27233232) (BS3_Supporting). The computational predictor REVEL gives a score of 0.049 which is below the threshold of 0.15, evidence that does not predict a damaging effect on AGAT function (BP4). There is a ClinVar entry for this variant (Variation ID: 205613). In summary, this variant meets the criteria to be classified as benign for AGAT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.0): BA1, BS3_Supporting, BP4.(Classification approved by the ClinGen CCDS VCEP on January 25, 2023). LINK:https://erepo.genome.network/evrepo/ui/classification/CA314868/MONDO:0012996/025

Frequency

Genomes: 𝑓 0.00059 ( 2 hom., cov: 32)
Exomes 𝑓: 0.00059 ( 3 hom. )

Consequence

GATM
NM_001482.3 missense

Scores

19

Clinical Significance

Benign reviewed by expert panel U:2B:7

Conservation

PhyloP100: 0.773

Publications

6 publications found
Variant links:
Genes affected
GATM (HGNC:4175): (glycine amidinotransferase) This gene encodes a mitochondrial enzyme that belongs to the amidinotransferase family. This enzyme is involved in creatine biosynthesis, whereby it catalyzes the transfer of a guanido group from L-arginine to glycine, resulting in guanidinoacetic acid, the immediate precursor of creatine. Mutations in this gene cause arginine:glycine amidinotransferase deficiency, an inborn error of creatine synthesis characterized by cognitive disability, language impairment, and behavioral disorders. [provided by RefSeq, Jul 2008]
GATM Gene-Disease associations (from GenCC):
  • AGAT deficiency
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Orphanet, Ambry Genetics, G2P
  • Fanconi renotubular syndrome 1
    Inheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
  • primary Fanconi syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -10 ACMG points.

BP4
For more information check the summary or visit ClinGen Evidence Repository.
BS3
For more information check the summary or visit ClinGen Evidence Repository.
BA1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GATMNM_001482.3 linkc.407C>T p.Thr136Met missense_variant Exon 3 of 9 ENST00000396659.8 NP_001473.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GATMENST00000396659.8 linkc.407C>T p.Thr136Met missense_variant Exon 3 of 9 1 NM_001482.3 ENSP00000379895.3

Frequencies

GnomAD3 genomes
AF:
0.000585
AC:
89
AN:
152126
Hom.:
2
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000193
Gnomad AMI
AF:
0.0274
Gnomad AMR
AF:
0.000197
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000779
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000370
AC:
93
AN:
251392
AF XY:
0.000420
show subpopulations
Gnomad AFR exome
AF:
0.000185
Gnomad AMR exome
AF:
0.0000289
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000544
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000765
Gnomad OTH exome
AF:
0.000163
GnomAD4 exome
AF:
0.000587
AC:
858
AN:
1461806
Hom.:
3
Cov.:
31
AF XY:
0.000589
AC XY:
428
AN XY:
727204
show subpopulations
African (AFR)
AF:
0.000179
AC:
6
AN:
33478
American (AMR)
AF:
0.0000224
AC:
1
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
26132
East Asian (EAS)
AF:
0.0000504
AC:
2
AN:
39690
South Asian (SAS)
AF:
0.0000116
AC:
1
AN:
86256
European-Finnish (FIN)
AF:
0.0000187
AC:
1
AN:
53416
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5768
European-Non Finnish (NFE)
AF:
0.000734
AC:
816
AN:
1111952
Other (OTH)
AF:
0.000513
AC:
31
AN:
60390
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.465
Heterozygous variant carriers
0
44
88
133
177
221
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
34
68
102
136
170
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.000585
AC:
89
AN:
152126
Hom.:
2
Cov.:
32
AF XY:
0.000579
AC XY:
43
AN XY:
74316
show subpopulations
African (AFR)
AF:
0.000193
AC:
8
AN:
41436
American (AMR)
AF:
0.000197
AC:
3
AN:
15264
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5202
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4826
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10594
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.000779
AC:
53
AN:
68024
Other (OTH)
AF:
0.00
AC:
0
AN:
2084
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.493
Heterozygous variant carriers
0
6
13
19
26
32
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000602
Hom.:
0
Bravo
AF:
0.000623
TwinsUK
AF:
0.000539
AC:
2
ALSPAC
AF:
0.00130
AC:
5
ESP6500AA
AF:
0.000227
AC:
1
ESP6500EA
AF:
0.000582
AC:
5
ExAC
AF:
0.000321
AC:
39
Asia WGS
AF:
0.000289
AC:
1
AN:
3478
EpiCase
AF:
0.000545
EpiControl
AF:
0.000711

ClinVar

Significance: Benign
Submissions summary: Uncertain:2Benign:7
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

Arginine:glycine amidinotransferase deficiency Uncertain:1Benign:2
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. -

Jan 23, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 25, 2023
ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel, ClinGen
Significance:Benign
Review Status:reviewed by expert panel
Collection Method:curation

The NM_001482.3:c.407C>T variant in GATM is a missense variant predicted to cause substitution of threonine by methionine at amino acid 136 (p.Thr136Met). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0007357 (95/129130 alleles) in the non-Finnish European population, which is higher than the ClinGen CCDS VCEP’s threshold for BA1 (>0.0005), and therefore meets this criterion (BA1). Expression of the variant in HeLa cells resulted in >50% wild type AGAT activity suggesting that this variant does not significantly impact protein function (PMID: 27233232) (BS3_Supporting). The computational predictor REVEL gives a score of 0.049 which is below the threshold of 0.15, evidence that does not predict a damaging effect on AGAT function (BP4). There is a ClinVar entry for this variant (Variation ID: 205613). In summary, this variant meets the criteria to be classified as benign for AGAT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 1.0): BA1, BS3_Supporting, BP4. (Classification approved by the ClinGen CCDS VCEP on January 25, 2023). -

not provided Uncertain:1Benign:2
Aug 28, 2020
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 27233232) -

Jan 09, 2017
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

GATM: BP4, BS2 -

not specified Benign:1
Jun 24, 2024
Athena Diagnostics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Jun 07, 2016
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Intellectual disability Benign:1
Jan 01, 2019
Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.050
BayesDel_addAF
Benign
-0.48
T
BayesDel_noAF
Benign
-0.51
CADD
Benign
15
DANN
Benign
0.86
DEOGEN2
Benign
0.31
T;.;.;T;T;T
Eigen
Benign
-0.68
Eigen_PC
Benign
-0.46
FATHMM_MKL
Benign
0.39
N
LIST_S2
Benign
0.56
T;T;T;T;T;.
M_CAP
Benign
0.0027
T
MetaRNN
Benign
0.0070
T;T;T;T;T;T
MetaSVM
Benign
-1.1
T
MutationAssessor
Benign
-0.46
N;N;.;.;.;.
PhyloP100
0.77
PrimateAI
Benign
0.31
T
PROVEAN
Benign
0.080
N;N;N;N;N;D
REVEL
Benign
0.049
Sift
Benign
0.12
T;T;T;T;T;.
Sift4G
Benign
0.14
T;T;.;T;.;.
Polyphen
0.0
B;B;.;.;.;.
Vest4
0.20
MVP
0.15
MPC
0.71
ClinPred
0.024
T
GERP RS
2.3
Varity_R
0.032
gMVP
0.49
Mutation Taster
=97/3
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs148564534; hg19: chr15-45661601; COSMIC: COSV101188036; COSMIC: COSV101188036; API